You are here

  • Home
  • Archive
  • Volume 11, Issue 7
  • Correction: Nivolumab serum concentration in metastatic melanoma patients could be related to outcome and enhanced immune activity: a gene profiling retrospective analysis

Article Text

Article menu

See original article:

Download PDFPDF

Correction
Correction: Nivolumab serum concentration in metastatic melanoma patients could be related to outcome and enhanced immune activity: a gene profiling retrospective analysis

https://doi.org/10.1136/jitc-2022-005132corr1

Statistics from Altmetric.com

    Request Permissions

    If you wish to reuse any or all of this article please use the link below which will take you to the Copyright Clearance Center’s RightsLink service. You will be able to get a quick price and instant permission to reuse the content in many different ways.

    Mallardo D, Giannarelli D, Vitale MG, et al. Nivolumab serum concentration in metastatic melanoma patients could be related to outcome and enhanced immune activity: a gene profiling retrospective analysis. J Immunother Cancer 2022;10:e005132. doi: 10.1136/jitc-2022-005132

    Figure 1 was incorrectly published in black and white. This has now been amended.